Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 25;S1198-743X(20)30234-2.
doi: 10.1016/j.cmi.2020.04.026. Online ahead of print.

Umifenovir Treatment Is Not Associated With Improved Outcomes in Patients With Coronavirus Disease 2019: A Retrospective Study

Affiliations
Free PMC article

Umifenovir Treatment Is Not Associated With Improved Outcomes in Patients With Coronavirus Disease 2019: A Retrospective Study

N Lian et al. Clin Microbiol Infect. .
Free PMC article

Abstract

Objectives: Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Umifenovir (Arbidol®) is an antiviral drug being used to treat influenza in Russia and China. This study aimed to investigate the effectiveness and safety of umifenovir for COVID-19.

Methods: A retrospective study was performed in a non-intensive care unit (ICU) ward in Jinyintan Hospital from 2 February 2020 to 20 March 2020. COVID-19 was confirmed by real-time reverse-transcriptase polymerase chain reaction (RT-PCR) assay of pharyngeal swab specimens. The confirmed patients were divided into the umifenovir group and the control group according to the use of umifenovir. The main outcomes were the rate of negative pharyngeal swab tests for SARS-CoV-2 within 1 week after admission and the time for the virus to turn negative. The negativity time of SARS-CoV-2 was defined as the first day of a negative test if the nucleic acid of SARS-CoV-2 was negative for two consecutive tests.

Results: A total of 81 COVID-19 patients were included, with 45 in the umifenovir group and 36 in the control group. Baseline clinical and laboratory characteristics were comparable between the two groups. Thirty-three out of 45 (73%) patients in the umifenovir group tested negative for SARS-CoV-2 within 7 days after admission, the number was 28/36 (78%) in the control group (p 0.19). The median time from onset of symptoms to SARS-CoV-2 turning negative was 18 days (interquartile range (IQR) 12-21) in the umifenovir group and 16 days (IQR 11-21) in the control group (p 0.42). Patients in the umifenovir group had a longer hospital stay than patients in the control group (13 days (IQR 9-17) vs 11 days (IQR 9-14), p 0.04). No deaths or severe adverse reactions were found in both groups.

Discussion: Umifenovir might not improve the prognosis or accelerate SARS-CoV-2 clearance in non-ICU patients. A randomized control clinical trial is needed to assess the efficacy of umifenovir.

Keywords: Antiviral intervention; Arbidol; Corona virus disease 2019; Effectiveness; Umifenovir.

Figures

Figure 1
Figure 1
Effectiveness of umifenovir in patients with COVID-19, a subgroup analysis based on CT scores. Data were presented as median (IQR). Abbreviations: COVID-19, coronavirus disease 2019; CT Score dif= CT Score (within 2 days of admission)- CT Score (at the 7th day after hospitalization); SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Similar articles

  • Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
    Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A; COVID-19 Lombardy ICU Network, Nailescu A, Corona A, Zangrillo A, Protti A, Albertin A, Forastieri Molinari A, Lombardo A, Pezzi A, Benini A, Scandroglio AM, Malara A, Castelli A, Coluccello A, Micucci A, Pesenti A, Sala A, Alborghetti A, Antonini B, Capra C, Troiano C, Roscitano C, Radrizzani D, Chiumello D, Coppini D, Guzzon D, Costantini E, Malpetti E, Zoia E, Catena E, Agosteo E, Barbara E, Beretta E, Boselli E, Storti E, Harizay F, Della Mura F, Lorini FL, Donato Sigurtà F, Marino F, Mojoli F, Rasulo F, Grasselli G, Casella G, De Filippi G, Castelli G, Aldegheri G, Gallioli G, Lotti G, Albano G, Landoni G, Marino G, Vitale G, Battista Perego G, Evasi G, Citerio G, Foti G, Natalini G, Merli G, Sforzini I, Bianciardi L, Carnevale L, Grazioli L, Cabrini L, Guatteri L, Salvi L, Dei Poli M, Galletti M, Gemma M, Ranucci M, Riccio M, Borelli M, Zambon M, Subert M, Cecconi M, Mazzoni MG, Raimondi M, Panigada M, Belliato M, Bronzini N, Latronico N, Petrucci N, Belgiorno N, Tagliabue P, Cortellazzi P, Gnesin P, Grosso P, Gritti P, Perazzo P, Severgnini P, Ruggeri P, Sebastiano P, Covello RD, Fernandez-Olmos R, Fumagalli R, Keim R, Rona R, Valsecchi R, Cattaneo S, Colombo S, Cirri S, Bonazzi S, Greco S, Muttini S, Langer T, Alaimo V, Viola U. Grasselli G, et al. JAMA. 2020 Apr 6;323(16):1574-81. doi: 10.1001/jama.2020.5394. Online ahead of print. JAMA. 2020. PMID: 32250385 Free PMC article.
  • Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein.
    Vankadari N. Vankadari N. Int J Antimicrob Agents. 2020 Apr 28:105998. doi: 10.1016/j.ijantimicag.2020.105998. Online ahead of print. Int J Antimicrob Agents. 2020. PMID: 32360231 Free PMC article.
  • SARS-CoV-2 is not detectable in the vaginal fluid of women with severe COVID-19 infection.
    Qiu L, Liu X, Xiao M, Xie J, Cao W, Liu Z, Morse A, Xie Y, Li T, Zhu L. Qiu L, et al. Clin Infect Dis. 2020 Apr 2:ciaa375. doi: 10.1093/cid/ciaa375. Online ahead of print. Clin Infect Dis. 2020. PMID: 32241022 Free PMC article.
  • Features, Evaluation and Treatment Coronavirus (COVID-19).
    Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Cascella M, et al. 2020 Apr 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. StatPearls. 2020 Jan–. PMID: 32150360 Free Books & Documents. Review.
  • The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.
    Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. Guo YR, et al. Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0. Mil Med Res. 2020. PMID: 32169119 Free PMC article. Review.
See all similar articles

References

    1. El Zowalaty M.E., Järhult J.D. From SARS to COVID-19: A previously unknown SARS- related coronavirus (SARS-CoV-2) of pandemic potential infecting humans - Call for a One Health approach. One Health (Amsterdam, Netherlands) 2020;9:100124.
    1. He F., Deng Y., Li W. Coronavirus disease 2019: What we know? J Med Virol. 2020
    1. Behzadi M.A., Leyva-Grado V.H. Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections. Front Microbiol. 2019;10:1327. - PMC - PubMed
    1. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020
    1. Sun P., Qie S., Liu Z., Ren J., Li K., Xi J. Clinical characteristics of 50466 hospitalized patients with 2019-nCoV infection. J Med Virol. 2020

LinkOut - more resources

Feedback